Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every two-month dosing;.
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome 2news.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 2news.com Daily Mail and Mail on Sunday newspapers.
– Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction.
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.